CRISPR Therapeutics Company

CRISPR Therapeutics is focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. They have licensed the foundational CRISPR/Cas9 patent estate for human therapeutic use from their scientific founder, Dr. Emmanuelle Charpentier, who co-invented the application of CRISPR/Cas9 for gene editing.
CRISPR Therapeutics’ vision is to cure serious human diseases at the molecular level using CRISPR-Cas9. The company is headquartered in Basel, Switzerland and has operations in London, UK.
Technology: Regenerative Medicine
Industry: Gene therapy
Headquarters: Cambridge, Massachusetts, United States
Founded Date: 7-5
Employees Number: 1-10
Funding Status: IPO
Investors Number: 9
Total Funding: $127M
Estimated Revenue: $100M to $500M
Last Funding Type: Series B

Visit Website
info@crisprtx.com
@crisprtx
Register and Claim Ownership